[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1556389T3 - Cephemforbindelser - Google Patents

Cephemforbindelser

Info

Publication number
DK1556389T3
DK1556389T3 DK03758919T DK03758919T DK1556389T3 DK 1556389 T3 DK1556389 T3 DK 1556389T3 DK 03758919 T DK03758919 T DK 03758919T DK 03758919 T DK03758919 T DK 03758919T DK 1556389 T3 DK1556389 T3 DK 1556389T3
Authority
DK
Denmark
Prior art keywords
cephem
Prior art date
Application number
DK03758919T
Other languages
English (en)
Other versions
DK1556389T6 (da
Inventor
Hidenori Ohki
Shinya Okuda
Toshio Yamanaka
Masaru Ohgaki
Ayako Toda
Kohji Kawabata
Satoshi Inoue
Keiji Misumi
Kenji Itoh
Kenji Satoh
Original Assignee
Astellas Pharma Inc
Wakunaga Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002952355A external-priority patent/AU2002952355A0/en
Priority claimed from AU2003904813A external-priority patent/AU2003904813A0/en
Application filed by Astellas Pharma Inc, Wakunaga Pharma Co Ltd filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of DK1556389T3 publication Critical patent/DK1556389T3/da
Publication of DK1556389T6 publication Critical patent/DK1556389T6/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/247-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK03758919.9T 2002-10-30 2003-10-27 Cephemforbindelser DK1556389T6 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002952355A AU2002952355A0 (en) 2002-10-30 2002-10-30 Cephem compounds
AU2003904813A AU2003904813A0 (en) 2003-09-04 Cephem Compounds
PCT/JP2003/013684 WO2004039814A1 (en) 2002-10-30 2003-10-27 Cephem compounds

Publications (2)

Publication Number Publication Date
DK1556389T3 true DK1556389T3 (da) 2007-11-26
DK1556389T6 DK1556389T6 (da) 2015-05-11

Family

ID=32231625

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03758919.9T DK1556389T6 (da) 2002-10-30 2003-10-27 Cephemforbindelser

Country Status (20)

Country Link
US (2) US7129232B2 (da)
EP (1) EP1556389B9 (da)
JP (1) JP4448821B2 (da)
KR (1) KR101023035B1 (da)
AR (1) AR041729A1 (da)
AT (1) ATE368042T1 (da)
BE (1) BE2016C002I2 (da)
BR (1) BRPI0315188B8 (da)
CA (1) CA2504730C (da)
DE (1) DE60315178T3 (da)
DK (1) DK1556389T6 (da)
ES (1) ES2290498T7 (da)
FR (1) FR16C0004I2 (da)
HK (1) HK1086566A1 (da)
HU (1) HUS1600008I1 (da)
LU (1) LU92943I2 (da)
NL (1) NL300793I1 (da)
PT (1) PT1556389E (da)
TW (1) TWI319403B (da)
WO (1) WO2004039814A1 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4251873B2 (ja) * 2001-05-01 2009-04-08 アステラス製薬株式会社 セフェム化合物
EP1556389B9 (en) * 2002-10-30 2015-09-09 Astellas Pharma Inc. Cephem compounds
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
EP1663245B1 (en) 2003-09-18 2010-04-07 Astellas Pharma Inc. Cephem compounds
US7511159B2 (en) 2003-12-25 2009-03-31 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
JP2009530228A (ja) * 2006-03-16 2009-08-27 アステラス製薬株式会社 セフェム化合物および抗菌薬としての利用
ITFE20060029A1 (it) * 2006-10-17 2008-04-18 Gruppo Kemon Spa Intermedi eterociclici primari per la colorazione ossidativa dei capelli a struttura pirazolica
WO2009049086A1 (en) 2007-10-09 2009-04-16 Larry Sutton Broad spectrum beta-lactamase inhibitors
MX369142B (es) * 2011-05-13 2019-10-30 Array Biopharma Inc Compuestos intermediarios de fórmula ii, útiles en la preparación de compuestos derivados de pirrolidinil como inhibidores de cinasa trka.
RS66326B1 (sr) 2011-09-09 2025-01-31 Merck Sharp & Dohme Llc Ceftolozan/tazobaktam za lečenje intrapulmonalnih infekcija
EP2628730B1 (en) * 2012-02-16 2017-12-06 Noxell Corporation Telescoping synthesis of 5-amino-4-nitroso-1-alkyl-1h-pyrazole salts
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
BR112015006868B1 (pt) 2012-09-27 2021-11-30 Merck Sharp & Dohme Corp Composição farmacêutica de tazobactam-arginina cristalina e composto beta-lactâmico, seu uso, método para fazer uma composição farmacêutica e uso de tazobactam-arginina cristalina e de composto beta-lactâmico
US20140274999A1 (en) * 2013-03-14 2014-09-18 Cubist Pharmaceuticals, Inc. Cephalosporin compositions and methods of manufacture
US20140274990A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
NZ700372A (en) 2013-03-15 2016-01-29 Merck Sharp & Dohme Ceftolozane antibiotic compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20160228448A1 (en) * 2013-09-27 2016-08-11 Merck Sharp & Dohme Corp. Solid Forms of Ceftolozane
US20150094293A1 (en) * 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
NZ727418A (en) 2014-05-15 2023-03-31 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
WO2016025813A1 (en) 2014-08-15 2016-02-18 Merck Sharp & Dohme Corp. Intermediates in the synthesis of cephalosporin compounds
CN110204558B (zh) * 2014-08-15 2022-05-06 默沙东公司 头孢菌素化合物的合成
US10000510B2 (en) 2014-08-18 2018-06-19 Merck Sharp & Dohme Corp. Salt forms of ceftolozane
WO2016095860A1 (en) * 2014-12-18 2016-06-23 Merck Sharp & Dohme Corp. Pyrazolyl carboxylic acid and pyrazolyl urea derivative compounds
US10059680B2 (en) 2014-12-18 2018-08-28 Merck Sharp & Dohme Corp. Thiadiazolyl-oximinoacetic acid derivative compounds
US20160176897A1 (en) 2014-12-23 2016-06-23 Merck Sharp & Dohme Corp. 7-aminocephem derivative compounds
WO2016109259A2 (en) * 2014-12-30 2016-07-07 Merck Sharp & Dohme Corp. Synthesis of cephalosporin compounds
CA2987158A1 (en) 2015-06-29 2017-01-05 Sandoz Ag Process for the preparation of carbamoylamino pyrazole derivatives
US10532058B2 (en) 2015-09-08 2020-01-14 Sandoz Ag Process for preparing ceftolozane from 7-aminocephalosporanic acid (7-ACA)
KR20180066264A (ko) 2015-12-10 2018-06-18 나에자-알지엠 파마슈티칼스 유엘씨 세펨 화합물, 그의 제조 및 용도
EP3468968B1 (en) 2016-06-06 2024-01-10 Merck Sharp & Dohme LLC Solid forms of ceftolozane and processes for preparing
CN107586305A (zh) * 2017-06-23 2018-01-16 浙江惠迪森药业有限公司 一种β‑内酰胺类化合物羧基及羟基保护基脱除方法
WO2019145784A2 (en) * 2018-01-26 2019-08-01 Legochem Biosciences, Inc. Combination therapies for multi-drug resistant pathogens
CN109369535A (zh) * 2018-11-07 2019-02-22 浙江东邦药业有限公司 一种氨基甲酰氨基吡唑衍生化合物的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR78245B (da) * 1980-09-12 1984-09-26 Ciba Geigy Ag
US5194432A (en) * 1985-11-22 1993-03-16 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
CA1293719C (en) * 1986-09-22 1991-12-31 Takao Takaya Cephem compounds and processes for preparation thereof
US5663163A (en) * 1987-09-07 1997-09-02 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds and processes for preparation thereof
US5210080A (en) * 1987-09-07 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
IE63094B1 (en) * 1987-09-14 1995-03-22 Fujisawa Pharmaceutical Co Cephem compound and a process for preparation thereof
US5173485A (en) * 1988-03-09 1992-12-22 Fujisawa Pharmaceutical Company, Ltd. Cephem compounds
GB8905301D0 (en) * 1989-03-08 1989-04-19 Fujisawa Pharmaceutical Co New cephem compound and a process for preparation thereof
US5215982A (en) * 1989-11-10 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
KR910015587A (ko) * 1990-02-27 1991-09-30 후지사와 토모키치로 세펨 화합물
GB9023479D0 (en) * 1990-10-29 1990-12-12 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
JPH09110877A (ja) 1995-10-17 1997-04-28 Katayama Seiyakushiyo:Kk セフェム化合物、その製造法及びそれを含有する抗菌剤
AUPN955596A0 (en) 1996-04-30 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New compound
TW526202B (en) * 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
JP4251873B2 (ja) * 2001-05-01 2009-04-08 アステラス製薬株式会社 セフェム化合物
EP1556389B9 (en) * 2002-10-30 2015-09-09 Astellas Pharma Inc. Cephem compounds
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
EP1663245B1 (en) * 2003-09-18 2010-04-07 Astellas Pharma Inc. Cephem compounds

Also Published As

Publication number Publication date
ATE368042T1 (de) 2007-08-15
JP4448821B2 (ja) 2010-04-14
HK1086566A1 (en) 2006-09-22
LU92943I2 (fr) 2016-03-14
ES2290498T3 (es) 2008-02-16
BE2016C002I2 (da) 2023-03-07
DE60315178T2 (de) 2008-04-30
NL300793I2 (da) 2016-03-15
DK1556389T6 (da) 2015-05-11
KR101023035B1 (ko) 2011-03-24
US20070037786A1 (en) 2007-02-15
CA2504730A1 (en) 2004-05-13
CA2504730C (en) 2011-04-12
US7129232B2 (en) 2006-10-31
PT1556389E (pt) 2007-11-08
DE60315178D1 (de) 2007-09-06
EP1556389B1 (en) 2007-07-25
HUS1600008I1 (hu) 2016-03-29
EP1556389B9 (en) 2015-09-09
TWI319403B (en) 2010-01-11
FR16C0004I1 (fr) 2016-03-25
WO2004039814A1 (en) 2004-05-13
NL300793I1 (da) 2016-03-15
EP1556389A1 (en) 2005-07-27
EP1556389B3 (en) 2015-04-01
ES2290498T7 (es) 2015-07-10
AR041729A1 (es) 2005-05-26
BRPI0315188B8 (pt) 2021-05-25
BRPI0315188B1 (pt) 2017-04-25
JP2006506459A (ja) 2006-02-23
US20040132994A1 (en) 2004-07-08
TW200410977A (en) 2004-07-01
BR0315188A (pt) 2005-09-06
DE60315178T3 (de) 2015-06-18
KR20050084897A (ko) 2005-08-29
FR16C0004I2 (fr) 2017-01-06

Similar Documents

Publication Publication Date Title
DE60315178D1 (de) Cephemverbindungen
ATE457980T1 (de) Aryloxime
ATE534648T1 (de) C-6-modifizierte indazolylpyrrolotriazine
ATE427876T1 (de) Luftkissenboot
ATE318817T1 (de) Aza-arylpiperazine
DE50212360D1 (de) Anfahrhilfesteuerungsvorrichtung
DE50212349D1 (de) Hirurgie
DE50301200D1 (de) Wischblatt
DE60326590D1 (de) Tend lamotrigin
DE60332518D1 (de) Strömungswegumschaltventil
DE602004026451D1 (de) Cephem-verbindungen
ATE349458T1 (de) Etonogestrelester
DE50305301D1 (de) Einspritzventil
NO20035131D0 (no) Boksfikstur
ATA1572002A (de) Managementspleisskassette
DE50301960D1 (de) Hydrolager
DE50302660D1 (de) Stopfmachine
DE50301464D1 (de) Schraubensicherung
ATE469773T1 (de) Zugöse
ATA4142004A (de) Trägerverbau
DE50303317D1 (de) Einschub-leistungsschalter
ATA19152002A (de) Hubkupplung
ATE396192T1 (de) N-sulfonylaminothiazole
DE50303658D1 (de) Postgutmessvorrichtung
DE50209283D1 (de) Tropfbewässerungsrohr